2023
Longitudinal Trends in Suicidal Thoughts and Behaviors Among US Military Veterans During the COVID-19 Pandemic
Fischer I, Nichter B, Na P, Norman S, Krystal J, Pietrzak R. Longitudinal Trends in Suicidal Thoughts and Behaviors Among US Military Veterans During the COVID-19 Pandemic. JAMA Psychiatry 2023, 80: 577-584. PMID: 37017978, PMCID: PMC10077136, DOI: 10.1001/jamapsychiatry.2023.0393.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesCOVID-19FemaleHumansLongitudinal StudiesMaleMiddle AgedMilitary PersonnelPandemicsRisk FactorsSubstance-Related DisordersSuicidal IdeationVeteransConceptsNew-onset suicidal ideationUS military veteransLifetime substance use disorderPast-year suicidal ideationSubstance use disordersSuicidal ideationSuicide planningMilitary veteransUse disordersPsychiatric distressCOVID-19 pandemicSuicidal thoughtsPopulation-based longitudinal studyEvidence-based preventionLongitudinal studyLongitudinal trendsCohort studyNational HealthUS veteransMAIN OUTCOMEVeterans StudySuicide attemptsSuicide riskVulnerable populationsVeterans
2018
Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia
Cheng WJ, Chen CH, Chen CK, Huang MC, Pietrzak RH, Krystal JH, Xu K. Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia. Schizophrenia Research 2018, 199: 313-318. PMID: 29510925, DOI: 10.1016/j.schres.2018.02.049.Peer-Reviewed Original ResearchMeSH KeywordsAdultCognitionCognitive DysfunctionExcitatory Amino Acid AntagonistsFemaleHumansKetamineMalePsychotic DisordersSchizophrenic PsychologySubstance-Related DisordersConceptsSZ patientsCognitive impairmentCognitive functionSocial-emotional cognitionCogstate Brief BatteryPsychomotor processing speedTreatment-seeking patientsSpatial problemsSymptom profilesSevere symptom profileVerbal memoryCognitive profileKetamine-dependent patientsVisual learningBrief batteryProcessing speedNegative Syndrome ScaleBiology of psychosisKetamine usersCognitive dysfunctionPersistent psychosisMemorySubscale scoresKetamine abuseMinority of users
2017
Alcohol Triggers Reemergence of Ketamine-Like Experience in a Ketamine Ex-User
Chang F, Xu K, Huang MC, Krystal JH. Alcohol Triggers Reemergence of Ketamine-Like Experience in a Ketamine Ex-User. Journal Of Clinical Psychopharmacology 2017, 37: 110-112. PMID: 28027112, PMCID: PMC5193231, DOI: 10.1097/jcp.0000000000000635.Peer-Reviewed Original Research
2016
Genome-wide significant loci for addiction and anxiety
Hodgson K, Almasy L, Knowles EE, Kent JW, Curran JE, Dyer TD, Göring HH, Olvera RL, Fox PT, Pearlson GD, Krystal JH, Duggirala R, Blangero J, Glahn DC. Genome-wide significant loci for addiction and anxiety. European Psychiatry 2016, 36: 47-54. PMID: 27318301, PMCID: PMC5483998, DOI: 10.1016/j.eurpsy.2016.03.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismAnxiety DisordersBehavior, AddictiveComorbidityFemaleGenetic LinkageHispanic or LatinoHumansMaleMiddle AgedPedigreePhenotypeSubstance-Related DisordersConceptsLinkage scanLinkage signalGenome-wide significant lociSignificant quantitative trait lociGenome-wide linkage scanBivariate linkage scanSignificant positive genetic correlationQuantitative trait lociGene of interestBivariate linkage analysisPositive genetic correlationAddiction phenotypeGenomic lociGenetic architectureTrait lociPleiotropic signalsSignificant lociChromosomal regionsAddiction geneticsGenetic underpinningsLinkage analysisPrevious GWASGenetic correlationsNovel regionRole of geneticsFKBP5 polymorphisms, childhood abuse, and PTSD symptoms: Results from the National Health and Resilience in Veterans Study
Watkins LE, Han S, Harpaz-Rotem I, Mota NP, Southwick SM, Krystal JH, Gelernter J, Pietrzak RH. FKBP5 polymorphisms, childhood abuse, and PTSD symptoms: Results from the National Health and Resilience in Veterans Study. Psychoneuroendocrinology 2016, 69: 98-105. PMID: 27078785, DOI: 10.1016/j.psyneuen.2016.04.001.Peer-Reviewed Original ResearchAdultAllelesChildChild AbuseGene-Environment InteractionGenetic Predisposition to DiseaseGenotypeHumansHypothalamo-Hypophyseal SystemLinkage DisequilibriumMalePituitary-Adrenal SystemPolymorphism, Single NucleotideRisk FactorsStress Disorders, Post-TraumaticSubstance-Related DisordersTacrolimus Binding ProteinsVeterans
2014
Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia
Leatherman SM, Liang MH, Krystal JH, Lew RA, Valley D, Thwin SS, Rosenheck RA. Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2014, 202: 13-17. PMID: 24375206, DOI: 10.1097/nmd.0000000000000069.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntipsychotic AgentsChronic DiseaseDrug Administration ScheduleFemaleHospitalizationHumansInjections, IntramuscularMaleMiddle AgedProportional Hazards ModelsPsychotic DisordersQuality of LifeRisk AssessmentRisperidoneSchizophreniaSchizophrenic PsychologySeverity of Illness IndexSubstance-Related DisordersTreatment OutcomeConceptsQuality of lifeOral antipsychoticsOral treatmentInjectable risperidoneCox regressionTreatment effectsLong-Acting Injectable RisperidoneBody mass indexPsychiatric service useSubstance abuse outcomesSubstance use outcomesLAI risperidonePrimary endpointStudy entryWhite patientsClinical outcomesMass indexUnstable patientsMedication compliancePsychiatric rehospitalizationChronic schizophreniaClinical trialsClinical subgroupsPsychiatric hospitalizationPsychiatric symptoms
2012
Planning the New National Institute on Substance Use and Addiction Disorders
Nestler EJ, Krystal JH. Planning the New National Institute on Substance Use and Addiction Disorders. Biological Psychiatry 2012, 72: 166-167. PMID: 22683089, DOI: 10.1016/j.biopsych.2012.05.011.Peer-Reviewed Original Research
2007
Imaging the Neurochemistry of Alcohol and Substance Abuse
Martinez D, Kim JH, Krystal J, Abi-Dargham A. Imaging the Neurochemistry of Alcohol and Substance Abuse. Neuroimaging Clinics Of North America 2007, 17: 539-555. PMID: 17983969, DOI: 10.1016/j.nic.2007.07.004.Peer-Reviewed Original Research
2006
The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia
Krystal JH, D’Souza D, Gallinat J, Driesen N, Abi-Dargham A, Petrakis I, Heinz A, Pearlson G. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotoxicity Research 2006, 10: 235-252. PMID: 17197373, DOI: 10.1007/bf03033360.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismComorbidityDiagnosis, Dual (Psychiatry)HumansMotivationRiskSchizophreniaSchizophrenic PsychologySubstance-Related DisordersConceptsSubstance abuse riskSubstance abuseSubstance abuse disordersAbuse riskSubstances of abuseNicotinic cholinergicPatient groupDopaminergic inputAbused substancesAbuse disordersSchizophrenic patientsDysphoric effectsAbuse liabilityHigh dosesLow dosesNegative symptomsReceptor functionAltered responseSchizophreniaSchizophrenic individualsRiskReward processingSubjective distressImpulsive behaviorDosesThe interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women
Amin Z, Mason GF, Cavus I, Krystal JH, Rothman DL, Epperson CN. The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women. Pharmacology Biochemistry And Behavior 2006, 84: 635-643. PMID: 16860856, DOI: 10.1016/j.pbb.2006.06.007.Peer-Reviewed Original ResearchConceptsGamma-aminobutyric acidNeuroactive steroidsMajor inhibitory neurotransmitterCentral nervous system responseProgesterone derivative allopregnanoloneMultiple neurotransmitter systemsProton magnetic resonance spectroscopySubstance use disordersNervous system responsesInhibitory neurotransmitterMenstrual cycleMenopausal transitionNeurotransmitter systemsHormonal fluctuationsPsychiatric disordersUse disordersAffective disordersPsychiatric syndromesNeuropsychiatric disordersNeuroendocrine systemSteroidsPreclinical researchDisordersAllopregnanoloneAminobutyric acid
2001
A neurobiological basis for substance abuse comorbidity in schizophrenia
Chambers R, Krystal J, Self D. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biological Psychiatry 2001, 50: 71-83. PMID: 11526998, PMCID: PMC2913410, DOI: 10.1016/s0006-3223(01)01134-9.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDisease SusceptibilityDopamineFrontal LobeHippocampusHumansNeurobiologyNucleus AccumbensSchizophreniaSchizophrenic PsychologySubstance-Related DisordersConceptsDrug rewardLong-term substance abuseMedication side effectsPrior drug exposureSubstance abuse comorbidityNeuropathology of schizophreniaPrimary disease symptomsAddictive behaviorsDrug-seeking behaviorHippocampal dysfunctionDrug exposureFrontal cortexNucleus accumbensHippocampal formationSchizophrenic patientsSide effectsCognitive impairmentNegative symptomsSubstance abuseAltered integrationNeural circuitrySymptomsSchizophreniaMotivational changesComorbidities
1999
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsSubstance abuseTerms of rehospitalizationComorbid substance abuseExacerbation of symptomsHealth care expensesSelf-medication hypothesisBetter prognosisMedical illnessPharmacotherapeutic approachesRational pharmacotherapyNonschizophrenic populationsPatientsVocational functionIllicit substancesCare expensesAbuseVulnerability hypothesisRehospitalizationExacerbationMedicationsPharmacotherapyPrognosisPsychostimulantsIllness
1997
Effect of alpha-methyl-para-tyrosine on response to cocaine challenge
Stine S, Krystal J, Petrakis I, Jatlow P, Heninger G, Kosten T, Chamey D. Effect of alpha-methyl-para-tyrosine on response to cocaine challenge. Biological Psychiatry 1997, 42: 181-190. PMID: 9232210, DOI: 10.1016/s0006-3223(96)00331-9.Peer-Reviewed Original ResearchConceptsDopamine metabolite homovanillic acidCocaine-induced euphoriaNorepinephrine metabolite 3Placebo-controlled studyBlood pressure responseMetabolite homovanillic acidReduced plasma levelsTyrosine hydroxylase inhibitorSerum cocaine levelsTuberoinfundibular dopamine systemAMPT pretreatmentAcute reductionIntranasal administrationPara-tyrosinePlasma levelsProlactin levelsCocaine challengeHomovanillic acidCatecholamine synthesisHeart rateHydroxylase inhibitorAlpha-methylDopamine systemCocaine levelsTherapeutic potential
1995
Mazindol treatment for cocaine dependence
Stine S, Krystal J, Kosten T, Charney D. Mazindol treatment for cocaine dependence. Drug And Alcohol Dependence 1995, 39: 245-252. PMID: 8556974, DOI: 10.1016/0376-8716(95)01174-4.Peer-Reviewed Original ResearchTryptophan depletion and attenuation of cue-induced craving for cocaine
Satel SL, Krystal JH, Delgado PL, Kosten TR, Charney DS. Tryptophan depletion and attenuation of cue-induced craving for cocaine. American Journal Of Psychiatry 1995, 152: 778-783. PMID: 7726319, DOI: 10.1176/ajp.152.5.778.Peer-Reviewed Original ResearchConceptsCue-induced cravingTryptophan depletionPlacebo conditionPotent serotonin reuptake blockerCue exposureSerotonin reuptake blockersDouble-blind designAmino acid drinkVisual analogue ratingsCocaine-dependent patientsAnalogue ratingsReuptake blockerAcute reductionPlasma levelsSerotonergic systemMale inpatientsAcid drinkTryptophan levelsDrug usePatientsCocaine useCocaineRelapseCravingTest sessions
1994
SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine
van Dyck C, Rosen M, Thomas H, McMahon T, Wallace E, O'Connor P, Sullivan M, Krystal J, Hoffer P, Woods S, Kosten T. SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine. Psychiatry Research 1994, 55: 181-191. PMID: 7701033, DOI: 10.1016/0925-4927(94)90013-2.Peer-Reviewed Original ResearchConceptsRegional cerebral blood flowRegional cerebral blood flow alterationsCerebral blood flow alterationsHexamethyl propylene amine oximeOpiate-induced analgesiaBlood flow alterationsSeverity of withdrawalCerebral blood flowOpiate-dependent patientsAnterior cingulate regionsAnterior cingulate cortexSingle photon emissionPlacebo administrationAmine oximeOpiate withdrawalRCBF ratiosWithdrawal severityBlood flowCingulate cortexCingulate regionsSignificant negative correlationBuprenorphineNaltrexonePlaceboPatientsSpecificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms
Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS. Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms. JAMA Psychiatry 1994, 51: 898-911. PMID: 7944878, DOI: 10.1001/archpsyc.1994.03950110058008.Peer-Reviewed Original ResearchConceptsVisual analog scaleAnalog scaleScale scoreVisual analog scale scoreYohimbine hydrochlorideAnalog scale scoreDouble-blind conditionsEffect of mCPPReceptor partial agonistEffects of ethanolNoradrenergic mechanismsIntravenous infusionPlasma levelsSerotonergic systemNoradrenergic systemPlaceboDiscriminative propertiesMale inpatientsYohimbinePlasma prolactinCortisol levelsPartial agonistSerotonergic contributionAlcohol dependenceDays of testing
1993
Effects of Cocaine on Hospital Course in Schizophrenia
SEIBYL J, SATEL S, ANTHONY D, SOUTHWICK S, KRYSTAL J, CHARNEY D. Effects of Cocaine on Hospital Course in Schizophrenia. The Journal Of Nervous And Mental Disease 1993, 181: 31-37. PMID: 8093475, DOI: 10.1097/00005053-199301000-00006.Peer-Reviewed Original ResearchConceptsSubstance useSuicidal ideationCocaine useLifetime drug use historyAvailable hospital recordsHigher hospitalization ratesHigher neuroleptic dosesNon-using patientsEffects of cocainePoor illness courseDrug use historySubstance use patternsHigh rateSchizophrenia clinicHospital courseNeuroleptic doseHospital recordsHospitalization ratesIllness courseInpatient chartsNeuroleptic dosesPsychiatric hospitalizationNeuroleptic dosingHospitalizationSchizophrenic patients
1992
Mazindol and cocaine addiction in schizophrenia
Seibyl J, Brenner L, Krystal J, Johnson R, Charney D. Mazindol and cocaine addiction in schizophrenia. Biological Psychiatry 1992, 31: 1179-1181. PMID: 1525287, DOI: 10.1016/0006-3223(92)90171-u.Peer-Reviewed Original ResearchChronic 3,4-Methylenedioxymethamphetamine (MDMA) Use: Effects on Mood and Neuropsychological Function?
Krystal J, Price L, Opsahl C, Ricaurte G, Heninger G. Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use: Effects on Mood and Neuropsychological Function? The American Journal Of Drug And Alcohol Abuse 1992, 18: 331-341. PMID: 1357957, DOI: 10.3109/00952999209026070.Peer-Reviewed Original ResearchConceptsNeuropsychological functionMDMA useChronic MDMA useWechsler Memory ScaleLeast mild impairmentMemory ScaleNeuropsychological batteryTime of testingMood effectsCognitive functionMemory deficitsMethylenedioxymethamphetamine (MDMA) useDepressed moodMood regulationPreliminary evidenceDeficitsMild impairmentClinical criteriaClinical examinationPreliminary findingsSelective serotoninMoodModerate impairmentAffective disordersPossible detrimental effects